Autolus Therapeutics Management
Management criteria checks 3/4
Autolus Therapeutics' CEO is Chris Itin, appointed in Mar 2016, has a tenure of 8.17 years. total yearly compensation is $2.45M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €4.04M. The average tenure of the management team and the board of directors is 2.6 years and 4.2 years respectively.
Key information
Chris Itin
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 22.5% |
| CEO tenure | 8.2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.6yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$551k | -US$208m |
| Sep 30 2023 | n/a | n/a | -US$158m |
| Jun 30 2023 | n/a | n/a | -US$155m |
| Mar 31 2023 | n/a | n/a | -US$152m |
| Dec 31 2022 | US$3m | US$502k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$164m |
| Jun 30 2022 | n/a | n/a | -US$155m |
| Mar 31 2022 | n/a | n/a | -US$146m |
| Dec 31 2021 | US$3m | US$543k | -US$142m |
| Sep 30 2021 | n/a | n/a | -US$143m |
| Jun 30 2021 | n/a | n/a | -US$147m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$4m | US$522k | -US$142m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$127m |
| Dec 31 2019 | US$5m | US$517k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$104m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$68m |
| Dec 31 2018 | n/a | n/a | -US$58m |
| Sep 30 2018 | US$2m | US$403k | -US$45m |
Compensation vs Market: Chris's total compensation ($USD2.45M) is above average for companies of similar size in the German market ($USD1.26M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Itin (59 yo)
8.2yrs
Tenure
US$2,449,092
Compensation
Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.2yrs | US$2.45m | 0.40% $ 4.0m | |
| Founder | 9.8yrs | no data | 0.26% $ 2.6m | |
| Senior VP & CFO | less than a year | no data | no data | |
| Senior VP & COO | 7.6yrs | no data | 0.042% $ 425.3k | |
| Senior VP & Chief Technical Officer | 3.3yrs | no data | 0.043% $ 428.7k | |
| Senior VP & Chief Human Resources Officer | 2.6yrs | no data | 0.015% $ 146.5k | |
| Senior VP | no data | no data | 0.018% $ 179.3k | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP of Legal Affairs & General Counsel and Secretary | 2.6yrs | no data | no data | |
| Senior VP & Chief Business Development Officer | less than a year | no data | 0.0031% $ 31.0k | |
| Senior Vice President of Project Management | less than a year | no data | no data | |
| Senior Vice President of Medical Affairs | 1.3yrs | no data | no data |
2.6yrs
Average Tenure
57.5yo
Average Age
Experienced Management: 6A3A's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.6yrs | US$2.45m | 0.40% $ 4.0m | |
| Independent Non-Executive Director | 2.5yrs | US$224.14k | 0% $ 0 | |
| Chairman of the Board | less than a year | no data | no data | |
| Independent Non-Executive Director | 6.2yrs | US$209.89k | 0.0038% $ 37.9k | |
| Independent Non-Executive Director | 9.8yrs | US$207.98k | 0.051% $ 516.7k | |
| Independent Non-Executive Director | 9.7yrs | US$201.77k | 0% $ 0 | |
| Independent Non-Executive Director | 8.3yrs | US$207.98k | 0% $ 0 | |
| Independent Non-Executive Director | 5.9yrs | US$216.11k | 0% $ 0 | |
| Non-Executive Director | less than a year | no data | 0% $ 0 | |
| Non-Executive Director | less than a year | US$171.92k | 0% $ 0 | |
| Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | less than a year | US$16.22k | 0% $ 0 |
4.2yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 6A3A's board of directors are considered experienced (4.2 years average tenure).